ClinicalTrials.gg
CompletedNCT04742738Updated Apr 18, 2023

Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)

A Phase 1/2 interventional study of GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1 and Normal saline (0.9% sodium chloride solution) - Stage 1 in COVID-19 (Healthy Volunteers), sponsored by SK Bioscience Co., Ltd.. Completed at 12 sites in Korea, Republic of. Open to participants aged 19 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by SK Bioscience Co., Ltd. (part of SK Chemicals Co., Ltd.) · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
19 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 90 studies in COVID-19 with a site in Korea, Republic of — 11 open to participants now, 19 under way, 6 of them phase 3. COVID-19 · Korea, Republic of.

Enrollment
36th of 72
260 · median 253
Started
2021
with 28 others
Phase 1/2
6 of 90
none open now
Registered
35th of 90
by date
Lead sponsor
4 of 90
SK Bioscience Co., Ltd.

Among the 90 studies in COVID-19 with a site in Korea, Republic of, this one is the 36th largest by enrollment of the 72 interventional ones that give a count, is one of 29 that started in 2021, is one of 6 in phase 1/2, and was the 35th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

11 of the 90 studies in COVID-19 with a site in Korea, Republic of are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 355 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 90 take children under 18; 134 take healthy volunteers.

This study: 19 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in COVID-19 with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a first-in-human, Phase I/II, randomized, placebo-controlled, observer-blinded, age-escalating study to assess the safety, reactogenicity and immunogenicity of a SK SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with Alum in healthy younger and older adults.

Read the detailed description

The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the candidate vaccine administered twice with 28-day interval in healthy adults including older adults.

A total of 260 healthy younger and older adults will be enrolled to receive 2 doses of either one GBP510 formulation (Test group 1 or 2) or placebo saline (Placebo group).

This study will consist of 2 stages, and a stepwise approach will be adopted as a safety precaution. Approximately 60 healthy adults aged 19 to 55 years will be enrolled and vaccinated first in Stage 1, and blinded safety data collected through 7 days after the last study vaccination will be reviewed by the sponsor, and then by the independent Data Safety Monitoring Board (DSMB) in an unblinded manner. Advancement to Stage 2 for further enrollment of 200 healthy younger and older adults aged 19 to 85 years will be determined if an acceptable safety profile is confirmed based on the sponsor and DSMB review. DSMB will recommend whether to proceed to the next stage or not, and DSMB may suggest discontinuation of the study or adjustment of dose and dosing regimen based on the safety review.

03

Conditions studied

  • COVID-19 (Healthy Volunteers)

Browse trials for

04

Who can participate

Ages eligible
19 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

Age

  1. For Stage 1, participant must be 19 to 55 years of age inclusive, at the time of signing the .

    For Stage 2, participant must be 19 to 85 years of age inclusive, at the time of signing the informed consent

    Type of Participant and Disease Characteristics

  2. Participants who are healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, and medical judgement of the investigator
  3. Participants who are able to attend all scheduled visits and comply with all study procedures.

    Weight

  4. (BMI) within the range 18-30 kg/m2 at screening (inclusive)

    Sex and /Barrier Requirements

  5. Female participants of must agree to be heterosexually inactive, or agree to consistently use at least one acceptable method of contraception from at least 4 weeks prior to the 1st study vaccination to 12 weeks after the last study vaccination
  6. Female participants with a negative urine or serum pregnancy test at screening

    Informed Consent

  7. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions

  1. Any respiratory symptoms (e.g. cough, sore throat), febrile illness (tympanic temperature >38°C), or acute illness within 72 hours prior to the 1st study vaccination. A prospective participant should not be included until 72 hours after the condition has resolved.
  2. History of virologically-confirmed COVID-19 disease, or definite or suspected exposure to anyone known to have SARS-CoV-2 infection
  3. History of virologically-confirmed SARS or MERS disease
  4. History of congenital, hereditary, acquired immunodeficiency, or disease
  5. Any positive test results for , C, or at screening
  6. History of bleeding disorder or thrombocytopenia which is contraindicating intramuscular vaccination in the investigator's opinion
  7. History of and severe allergic reaction (e.g. anaphylaxis, Guillain-Barre syndrome) to any vaccines or components of the study intervention
  8. History of within 5 years prior to the 1st study vaccination
  9. Significant chronic illness that, in the opinion of the investigator, might increase risk of severe COVID-19, or interfere with the evaluation of the study objectives (e.g. asthma, chronic pulmonary disease, cardiovascular disease, chronic liver disease, diabetes mellitus, uncontrolled hypertension, renal disorders)
  10. History of, or planned surgery under general anesthesia from 1 year prior to the 1st study vaccination through the study period
  11. Any other conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g. neurologic or psychiatric conditions)
  12. Female participants who are pregnant or breastfeeding
  13. (Only for Stage 1) Current smokers or a recent smoking history within 12 weeks prior to the 1st study vaccination. Occasional smokers who smoke up to 10 cigarettes per month may be allowed to participate at the investigator's discretion

    Prior/Concomitant therapy

  14. Receipt of any medications or vaccinations intended to prevent COVID-19.
  15. Receipt of any vaccine within 4 weeks prior to the 1st study vaccination or planned receipt of any vaccine from enrollment through 28 days after the last study vaccination (Visit 7), except for influenza vaccination, which may be received at least 2 weeks prior to the 1st study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines
  16. Receipt of immunoglobulins and/or any blood or blood products within 12 weeks prior to the 1st study vaccination
  17. Chronic use (more than 2 consecutive weeks) of therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic therapy (≥10mg prednisone/day or equivalent for more than 2 consecutive weeks) within 12 weeks prior to the 1st vaccination. The use of topical and nasal glucocorticoids will be permitted.

    Prior/Concurrent Clinical Study Experience

  18. Participation in another clinical study involving study intervention within 6 months prior to the 1st study vaccination, or concurrent, planned participation in another clinical study with study intervention during this study period.

    Other Exclusions

  19. Investigators, or study staff who are directly involved in the conduct of this study or supervised by the investigator, and their respective family members.
  20. Healthcare worker or emergency response personnel in an occupation with a high risk of exposure to SARS-CoV-2
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    Test group 1 - Stage 1 Low dose-level Cohort

    2 doses of GBP510 adjuvanted with Alum (Receptor Binding Domain (RBD) 10μg/dose), 1 dose each on Days 0 and 28.

    Biological: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1

  • Placebo comparator
    Placebo group - Stage 1 Low dose-level Cohort

    2 doses of Placebo Saline, 1 dose each on Days 0 and 28.

    Other: Normal saline (0.9% sodium chloride solution) - Stage 1

  • Experimental
    Test group 2 - Stage 1 High dose-level Cohort

    2 doses of GBP510 adjuvanted with Alum (RBD 25μg/dose), 1 dose each on Days 0 and 28.

    Biological: GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1

  • Placebo comparator
    Placebo group - Stage 1 High dose-level Cohort

    2 doses of Placebo Saline, 1 dose each on Days 0 and 28.

    Other: Normal saline (0.9% sodium chloride solution) - Stage 1

  • Experimental
    Test group 1 - Stage 2

    2 doses of GBP510 adjuvanted with Alum (RBD 10μg/dose), 1 dose each on Days 0 and 28.

    Biological: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2

  • Experimental
    Test group 2 - Stage 2

    2 doses of GBP510 adjuvanted with Alum (RBD 25μg/dose), 1 dose each on Days 0 and 28.

    Biological: GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2

  • Placebo comparator
    Placebo group - Stage 2

    2 doses of Placebo Saline, 1 dose each on Days 0 and 28.

    Other: Normal saline (0.9% sodium chloride solution)- Stage 2

Interventions

  • BiologicalGBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1

    Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.

    Also known as: GBP510-Alum-10μg

  • OtherNormal saline (0.9% sodium chloride solution) - Stage 1

    Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.

  • BiologicalGBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1

    Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.

    Also known as: GBP510-Alum-25μg

  • OtherNormal saline (0.9% sodium chloride solution) - Stage 1

    Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.

  • BiologicalGBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2

    Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.

    Also known as: GBP510-Alum-10μg

  • BiologicalGBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2

    Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.

    Also known as: GBP510-Alum-25μg

  • OtherNormal saline (0.9% sodium chloride solution)- Stage 2

    Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.

06

What researchers measure

Primary outcomes

  1. Occurrence of immediate systemic reactions - Stage 1

    Time frame: Through 30 minutes (2 hours for sentinel participants) post-vaccination

  2. Occurrence of solicited local Adverse Events (AEs) during 7 days post each vaccination - Stage 1

    Time frame: Through 7 days post-vaccination

  3. Occurrence of solicited systemic AEs during 7 days post each vaccination - Stage 1

    Time frame: Through 7 days post-vaccination

  4. Occurrence of unsolicited AEs during 28 days post each vaccination - Stage 1

    Time frame: Through 28 days post-vaccination

  5. Occurrence of Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs) and Adverse Events of Special Interest (AESIs) during the whole study period - Stage 1

    Time frame: Through Day 0 to Day 365 post last vaccination

  6. (Only in Sentinel group) Occurrence of out-of-normal range clinical laboratory test results (including change from baseline values) during 7 days post 1st vaccination - Stage 1

    Time frame: Through 7 days post 1st vaccination

  7. GMT of IgG antibody to the SARS-CoV-2 RBD measured by Enzyme-linked Immunosorbent Assay (ELISA) - Stage 2

    Time frame: Through Day 365 post last vaccination

  8. GMFR of IgG antibody to the SARS-CoV-2 RBD from baseline measured by ELISA - Stage 2

    Time frame: Through Day 365 post last vaccination

  9. Percentage of participants with ≥ 4-fold rise from baseline in ELISA IgG titer - Stage 2

    Time frame: Through Day 365 post last vaccination

  10. GMT of neutralizing antibody to the SARS-CoV-2 measured by pseudovirus and wild-type virus neutralization assays - Stage 2

    Time frame: Through Day 365 post last vaccination

  11. GMFR of neutralizing antibody to the SARS-CoV-2 from baseline measured by pseudovirus and wild-type virus neutralization assays - Stage 2

    Time frame: Through Day 365 post last vaccination

  12. Percentage of participants with ≥ 4-fold rise from baseline in pseudovirus and wild-type neutralizing antibody titer - Stage 2

    Time frame: Through Day 365 post last vaccination

  13. Cell-mediated response for both Th1 and Th2 (e.g. INF-γ, IL-4 using Enzyme-linked ImmunoSpot (ELISpot) or other system) - Stage 2

    Time frame: Through Day 28 post last vaccination

Secondary outcomes

  1. GMT of IgG antibody to the SARS-CoV-2 RBD measured by ELISA - Stage 1

    Time frame: Through Day 365 post last vaccination

  2. GMFR of IgG antibody to the SARS-CoV-2 RBD from baseline measured by ELISA - Stage 1

    Time frame: Through Day 365 post last vaccination

  3. Percentage of participants with ≥ 4-fold rise from baseline in ELISA IgG titer - Stage 1

    Time frame: Through Day 365 post last vaccination

  4. GMT of neutralizing antibody to the SARS-CoV-2 measured by pseudovirus and wild-type virus neutralization assays - Stage 1

    Time frame: Through Day 365 post last vaccination

  5. GMFR of neutralizing antibody to the SARS-CoV-2 from baseline measured by pseudovirus and wild-type virus neutralization assays - Stage 1

    Time frame: Through Day 365 post last vaccination

  6. Percentage of participants with ≥ 4-fold rise from baseline in pseudovirus and wild-type neutralizing antibody titer - Stage 1

    Time frame: Through Day 365 post last vaccination

  7. Cell-mediated response for both Th1 and Th2 (e.g. INF-γ, IL-4 using ELISpot or other system) - Stage 1

    Time frame: Through Day 28 post last vaccination

  8. Occurrence of immediate systemic reactions - Stage 2

    Time frame: Through 30 minutes (2 hours for elderly participants aged 75 years and older) post-vaccination

  9. Occurrence of solicited local AEs during 7 days post each vaccination - Stage 2

    Time frame: Through 7 days post-vaccination

  10. Occurrence of solicited systemic AEs during 7 days post each vaccination - Stage 2

    Time frame: Through 7 days post-vaccination

  11. Occurrence of unsolicited AEs during 28 days post each vaccination - Stage 2

    Time frame: Through 28 days post-vaccination

  12. Occurrence of SAEs, MAAEs and AESIs during the whole study period - Stage 2

    Time frame: Through Day 0 to Day 365 post last vaccination

07

Study locations

12 sites
  • Korea University Ansan Hospital
    Ansan, Korea, Republic of
  • Dong-A University Hospital
    Busan, Korea, Republic of
  • Kyungpook National University Chilgok Hospital
    Daegu, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, Korea, Republic of
  • Inha University Hospital
    Incheon, Korea, Republic of
  • Ewha Womans University Medical Center
    Seoul, Korea, Republic of
  • Hallym University Medical Center
    Seoul, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
  • Ajou University Hospital
    Suwon, Korea, Republic of
08

References and documents

Publications

  • Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, Roltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M, Fiala B, Carter L, White AG, Trisal M, Hsieh CL, Russell-Lodrigue K, Monjure C, Dufour J, Spencer S, Doyle-Meyers L, Bohm RP, Maness NJ, Roy C, Plante JA, Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O'Hagan DT, Van Der Most R, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S, Montefiori D, Boyd SD, Flynn JL, Alter G, Villinger F, Kleanthous H, Rappaport J, Suthar MS, King NP, Veesler D, Pulendran B. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021 Jun;594(7862):253-258. doi: 10.1038/s41586-021-03530-2. Epub 2021 Apr 19. PubMed 33873199 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jul 2021, 6 months.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 6 months is below that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2021
First posted
Feb 8, 2021
StartActual
Jan 20, 2021
Primary completionActual
Jul 30, 2021
CompletionActual
Jul 7, 2022
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04742738
Collaborators
Coalition for Epidemic Preparedness Innovations
Responsible party
Sponsor
First posted
Feb 8, 2021
Start date
Jan 20, 2021
Primary completion
Jul 30, 2021
Completion
Jul 7, 2022
Last update
Apr 18, 2023

Study contacts

Hee Jin Cheong
principal investigator · Korea University Guro Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion